JNJ-10397049
JNJ-10397049 is a pharmaceutical compound developed by Johnson & Johnson, a multinational corporation that specializes in pharmaceuticals, medical devices, and consumer packaged goods. JNJ-10397049 is a potent and selective inhibitor of the serotonin transporter (SERT), which is primarily responsible for the reuptake of serotonin from the synaptic cleft back into the presynaptic neuron. This compound has been studied for its potential use in the treatment of depression and anxiety disorders.
Chemistry[edit | edit source]
JNJ-10397049 is a small molecule compound. Its chemical structure and properties are proprietary information of Johnson & Johnson. As a selective serotonin reuptake inhibitor (SSRI), it is designed to bind to the serotonin transporter, thereby inhibiting the reuptake of serotonin and increasing its availability in the synaptic cleft.
Pharmacology[edit | edit source]
The primary mechanism of action of JNJ-10397049 is the inhibition of the serotonin transporter. By blocking the reuptake of serotonin, this compound increases the concentration of serotonin in the synaptic cleft, which can enhance serotonergic neurotransmission. This mechanism is similar to that of other SSRIs, which are commonly used in the treatment of depression and anxiety disorders.
Clinical Trials[edit | edit source]
JNJ-10397049 has undergone preclinical and early-phase clinical trials. The results of these trials have not been publicly disclosed by Johnson & Johnson. The safety, efficacy, and optimal dosing of this compound remain to be determined in future clinical trials.
Potential Therapeutic Uses[edit | edit source]
The primary potential therapeutic use of JNJ-10397049 is in the treatment of depression and anxiety disorders. By increasing the availability of serotonin in the synaptic cleft, this compound could potentially alleviate the symptoms of these disorders. However, further research is needed to confirm its efficacy and safety in these indications.
See Also[edit | edit source]
- Johnson & Johnson
- Serotonin transporter
- Selective serotonin reuptake inhibitor
- Depression
- Anxiety disorder
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
